The Zürich Summit was attended by global experts in menopause and related issues. It reviewed the evidence on the safety, risks and benefits of HRT in the first few years of the menopause, looking at 4 main areas of controversy: cardiovascular health, breast issues, cognition, and bone issues. Summit members compared public perception with actual safety, and are now issuing a state-of-the science summary, to enable women and clinicians to make informed judgements about whether or not to use HRT in early menopause.
Professor Amos Pines, President of the International Menopause Society, will present the Summit findings at the World Congress on the Menopause in Madrid on 20th May.
Background – the WHI Study
Hormone replacement therapy (HRT) use declined after the Women’s Health Initiative (WHI) study results were published in 2002. Initial results from the WHI study seemed to show that women taking HRT were at greater risk of breast cancer and heart disease, and this study had a dramatic effect on public perceptions and confidence in the use of HRT. However, since the first WHI information was released, it has become apparent that the study group was not completely representative of women taking HRT, and was characterized by a high incidence of several important risk factors, unusual in younger women around their menopause. For example:
The average age of women in the WHI study was 63 years of age, which is a decade older than the age at which most women begin taking HRT
Of women randomly assigned in the WHI study, 36% had hypertension, 49% were current or past smokers, and 34% were clinically obese, which are all factors which would contribute to increased health problems.
In addition, the reporting of the study did not make clear that different HRTs have different risks and benefits, but most importantly the most recent reports from WHI have clearly shown that the age at which HRT is started is critical. Most experts now agree that the fall-out from the initial WHI results has led to public concern about HRT use, which is not justified by the clinical evidence.
The Zürich Summit
The Zürich Summit was called to review the current evidence, and to review the risks and benefits of using HRT for women in early menopause. Forty of the world’s leading menopause experts met to review public perceptions, risks and benefits. Their main conclusions were:Cardiovascular issues
Short-to-medium term use of oestrogen-only HRT does not show this effect. The key message is that each woman should discuss her general health, and risk factors such as a family history, smoking, etc., with her own doctor, but generally healthy women (i.e. with no other breast cancer risk factors) entering the menopause should have no fears.Bone
Presenting the data at the Madrid Menopause congress, International Menopause Society President Professor Amos Pines (Tel-Aviv, Israel) said:
"This is positive news about HRT in the early menopause years, between the ages of 50 and 59. The Zürich Summit is the most important menopause workshop to discuss this issue, and it would be hard to find a more distinguished group of experts in the field. Their conclusions are that, for most women entering the menopause, HRT is a good and safe option. Of course, each woman is an individual, and HRT use should be decided after discussions with her doctor".
Dr David Sturdee (Solihull, UK), who will take over the IMS Presidency at the Madrid meeting, said:
"HRT is the most effective treatment for menopausal symptoms, but press reports over the last few years have made it difficult for many women to consider its use. The conclusions of this Summit show that it is generally safe and effective. Like all medicines, it needs to be used appropriately, but it is essential that women in early menopause who are suffering menopausal symptoms should have the option of using HRT".
Thomas Parkhill | alfa
Organ-on-a-chip mimics heart's biomechanical properties
23.02.2017 | Vanderbilt University
Researchers identify cause of hereditary skeletal muscle disorder
22.02.2017 | Klinikum der Universität München
On January 15, 2009, Chesley B. Sullenberger was celebrated world-wide: after the two engines had failed due to bird strike, he and his flight crew succeeded after a glide flight with an Airbus A320 in ditching on the Hudson River. All 155 people on board were saved.
On January 15, 2009, Chesley B. Sullenberger was celebrated world-wide: after the two engines had failed due to bird strike, he and his flight crew succeeded...
Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...
The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.
The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...
Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...
13.02.2017 | Event News
10.02.2017 | Event News
09.02.2017 | Event News
27.02.2017 | Materials Sciences
27.02.2017 | Interdisciplinary Research
27.02.2017 | Life Sciences